A study shows cannabis is now the most common impairing substance in Canadian driving collisions
FDA advisers back Eli Lilly's Alzheimer's drug donanemab, citing its benefits over risks like brain swelling
Bill C-64 passes in House of Commons, paving the way for a $1.5bn universal pharmacare program
According to Manulife's Employee Health Report, employees are increasingly using anti-obesity meds
Optimi Health can now export psilocybin and MDMA to Australia, marking a key step in the medical psychedelics market
A new study shows that semaglutide lowers risks of major kidney and heart events in diabetes patients
